RecruitingPhase 2

Corticosteroids to Treat Pancreatitis

United States86 participantsStarted 2022-03-06

Plain-language summary

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult (≥18 years)
✓. Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.
✓. Admission or planned admission to an intensive care unit
✓. SOFA disease severity score ≥3 (or at least 3 points above a known baseline)

Exclusion criteria

✕. Known diagnosis of autoimmune pancreatitis
✕. Existing clinical indication for corticosteroids at a dose \>5mg of oral prednisone daily (or equivalent)
✕. Contraindication to receiving corticosteroids
✕. Protected populations (prisoners)
✕. Pregnancy

What they're measuring

Severity of Illness Measure

Timeframe: Enrollment to 72 hours

Trial details

NCT IDNCT05160506

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

Michael Donnino, MD

6177542295 mdonnino@bidmc.harvard.edu

View on ClinicalTrials.gov More Pancreatitis trials